Pseudomonas aeruginosa
Morphology
|
Motile gram-negative aerobic bacteria, plump-shaped rods, with polar flagella which
have an important role in pathogenicity, non-spore forming
|
---|---|
Disease
|
Pneumonia, bacteremia, wound infections, urinary tract infections, swimmer's ear,
eye infections related to use of contact lenses.
|
Zoonosis
|
none
|
Host Range
|
Humans, Animals, Plants
|
---|---|
Modes of Transmission
|
Direct contact by inhalation of aerosols. Direct contact by aspiration of contaminated
water (tap or distilled). Direct contact by exposure of wounds to contaminated materials.
Indirectly by contact of mucous membranes with discharges from infected conjunctivae
or infected respiratory secretions.
|
Signs and Symptoms
|
Conjunctivitis, Upper Respiratory Infections, Pneumonia, Urinary Tract Infections,
Wound Infection.
|
Infectious Dose
|
unknown
|
Incubation Period
|
Variable depending on infection. Eye infection is 24 to 72 hours.
|
Prophylaxis
|
Antibiotic Prophylaxis
|
---|---|
Vaccines
|
None available
|
Treatment
|
Aggressive antibiotic therapy for severe infections; Local application of antibiotic
ointment or drops for skin or eye infections. Pseudomonas aeruginosa is intrinsically
resistant to many common antibiotics.
|
Surveillance
|
Bacteriological identification of infection.
|
MSU Requirements
|
Report any exposures
|
Laboratory Acquired Infections (LAIs)
|
None reported to date. However, this is an opportunistic pathogen and there is the
possibility of severe to fatal infection in the immunocompromised.
|
---|---|
Sources
|
Clinical Specimen: Respiratory secretions, wound exudates, blood, urine. Environmental
Reservoir: Water, infected solutions (IV, disinfectants, soap). Cultures, frozen stocks,
other samples described in IBC protocol.
|
Canadian MSDS
|
|
---|---|
BMBL
|
|
CDC
|
|
NIH Guidelines
|
Risk Group 2
|
Agents that are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available. |
---|---|
BSL2
|
For all procedures involving suspected or known infectious specimen or cultures.
|
ABSL2
|
For all procedures utilizing infected animals.
|
Small
|
Notify others working in the lab. Remove PPE and don new PPE. Cover area of the spill
with absorbent material and add fresh 1:10 bleach:water. Allow 20 munutes (or as directed)
of contact time. After 20 minutes, cleanup and dispose of materials.
|
---|---|
Large
|
|
Mucous membrane
|
Flush eyes, mouth, or nose for 5 minutes at eyewash station.
|
---|---|
Other Exposures
|
Wash area with soap and water for 5 minutes.
|
Reporting
|
Immediately report incident to supervisor, complete a First Report of Injury form, and submit to Safety and Risk Management.
|
Medical Follow-up
|
During business hours: Bridger Occupational Health 3406 Laramie Drive. Weekdays 8am -6pm. Weekends 9am-5pm
After business hours: Bozeman Deaconess Hospital Emergency Room 915 Highland Blvd Bozeman, MT |
Disinfection
|
Susceptible to 1:10 bleach:water, 70 % ethanol and 2 % gluteraldehyde, 2 % formaldehyde.
Alcohol contained disinfectants recommended for resistant strains.
|
---|---|
Inactivation
|
Inactivated by moist heat (15 minutes at 121° C) and dry heat (1 hour at 160-170°
C).
|
Survival Outside Host
|
Survives for several months in water with minimal nutrients.
|
Minimum PPE Requirements
|
Lab coat, disposable gloves, safety glasses, closed toed shoes, long pants
|
---|---|
Additional Precautions
|
Additioanl PPE may be required depending on lab specific SOPs and IBC Protocol. |